| Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study JK Sicklick, S Kato, R Okamura, M Schwaederle, ME Hahn, CB Williams, ... Nature medicine 25 (5), 744-750, 2019 | 549 | 2019 |
| Comparative effects of TCDD, endrin, naphthalene and chromium (VI) on oxidative stress and tissue damage in the liver and brain tissues of mice D Bagchi, J Balmoori, M Bagchi, X Ye, CB Williams, SJ Stohs Toxicology 175 (1-3), 73-82, 2002 | 153 | 2002 |
| Acute and chronic stress-induced oxidative gastrointestinal injury in rats, and the protective ability of a novel grape seed proanthocyanidin extract M Bagchi, M Milnes, C Williams, J Balmoori, X Ye, S Stohs, D Bagchi Nutrition research 19 (8), 1189-1199, 1999 | 153 | 1999 |
| Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1 R Balusu, W Fiskus, R Rao, DG Chong, S Nalluri, U Mudunuru, H Ma, ... Blood, The Journal of the American Society of Hematology 118 (11), 3096-3106, 2011 | 144 | 2011 |
| Utility of genomic analysis in circulating tumor DNA from patients with carcinoma of unknown primary S Kato, N Krishnamurthy, KC Banks, P De, K Williams, C Williams, ... Cancer research 77 (16), 4238-4246, 2017 | 120 | 2017 |
| Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer RJ Hartmaier, SE Trabucco, N Priedigkeit, JH Chung, CA Parachoniak, ... Annals of oncology 29 (4), 872-880, 2018 | 103 | 2018 |
| Acute and chronic stress-induced oxidative gastrointestinal mucosal injury in rats and protection by bismuth subsalicylate D Bagchi, OR Carryl, MX Tran, M Bagchi, A Garg, MM Milnes, CB Williams, ... Molecular and cellular biochemistry 196, 109-116, 1999 | 103 | 1999 |
| Single gene prognostic biomarkers in ovarian cancer: a meta-analysis S Willis, VM Villalobos, O Gevaert, M Abramovitz, C Williams, BI Sikic, ... PloS one 11 (2), e0149183, 2016 | 101 | 2016 |
| RET rearrangements are actionable alterations in breast cancer BS Paratala, JH Chung, CB Williams, B Yilmazel, W Petrosky, K Williams, ... Nature communications 9 (1), 4821, 2018 | 98 | 2018 |
| A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK N Dey, C Williams, B Leyland-Jones, P De American journal of translational research 7 (4), 733, 2015 | 74 | 2015 |
| Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC 412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid … CB Williams, S Kambhampati, W Fiskus, J Wick, C Dutreix, S Ganguly, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33 (12 …, 2013 | 72 | 2013 |
| Role of p53 tumor suppressor gene in the toxicity of TCDD, endrin, naphthalene, and chromium (VI) in liver and brain tissues of mice D Bagchi, J Balmoori, M Bagchi, X Ye, CB Williams, SJ Stohs Free Radical Biology and Medicine 28 (6), 895-903, 2000 | 56 | 2000 |
| Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study JK Sicklick, S Kato, R Okamura, H Patel, M Nikanjam, PT Fanta, ME Hahn, ... Genome medicine 13, 1-14, 2021 | 46 | 2021 |
| Mutation matters in precision medicine: A future to believe in N Dey, C Williams, B Leyland-Jones, P De Cancer treatment reviews 55, 136-149, 2017 | 45 | 2017 |
| Utilization of collaborative practice agreements between physicians and pharmacists as a mechanism to increase capacity to care for hematopoietic stem cell transplant recipients JA Merten, JF Shapiro, AM Gulbis, KV Rao, J Bubalo, S Lanum, ... Biology of Blood and Marrow Transplantation 19 (4), 509-518, 2013 | 44 | 2013 |
| Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in … CB Williams, SD Day, MD Reed, EA Copelan, T Bechtel, HL Leather, ... Biology of Blood and Marrow Transplantation 10 (9), 614-623, 2004 | 38 | 2004 |
| Treatment‐, patient‐, and disease‐related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia E Irvine, C Williams Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33 (8 …, 2013 | 35 | 2013 |
| Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation J McGuirk, G Hao, W Hou, S Abhyankar, C Williams, W Yan, J Yuan, ... Journal of hematology & oncology 2, 1-12, 2009 | 26 | 2009 |
| Survival analysis of adverse effects data in the Beta‐Blocker Heart Attack Trial BR Davis, CD Furberg, CB Williams Clinical Pharmacology & Therapeutics 41 (6), 611-615, 1987 | 21 | 1987 |
| Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after … T Meißner, A Mark, C Williams, WE Berdel, S Wiebe, A Kerkhoff, ... Molecular Case Studies 3 (4), a001677, 2017 | 18 | 2017 |
